scPharmaceuticals - Q1 2024
May 14, 2024
Transcript
Operator (participant)
Good afternoon, ladies and gentlemen, and welcome to the scPharmaceuticals First Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. Following the presentation, we will conduct a question-and-answer session. If at any time during this call you require immediate assistance, please press star zero for an operator. Also note that the call is being recorded Tuesday, May 14, 2024. I would like to turn the conference over to PJ Keller, Investor Relations. Please go ahead.
PJ Kelleher (Head of Investor Relations)
Thank you, operator. Before turning the call over to management, I would like to make the following remarks concerning forward-looking statements. All statements on this conference call other than historical facts are forward-looking statements within the meaning of the Federal Securities laws, including but not limited to, statements regarding scPharmaceuticals expected future financial results, management's expectations and plans for the business, the ongoing commercialization and marketing of FUROSCIX, and the potential label expansion and other regulatory approval of FUROSCIX.
The words anticipate, believe, estimate, expect, intend, guidance, confidence, target, project, and other similar expressions are used typically to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance and may involve and are subject to certain risks and uncertainties and other important factors that may affect scPharmaceuticals business, financial condition, and other operating results. These include, but are not limited to, the risk factors and other qualifications contained in scPharmaceuticals' annual report on Form 10-K, quarterly reports on
Form 10-Q, and other reports filed by the company with the SEC to which your attention is directed. Actual outcomes and results may differ materially from what is expressed or implied by these forward-looking statements. Any forward-looking statements made in this conference call, including responses to your questions, are based on current expectations as of today, and scPharmaceuticals expressly disclaims any intent or obligation to update these forward-looking statements except as required by law. It is now my pleasure to turn the call over to
Mr. John Tucker, Chief Executive Officer of scPharmaceuticals. John?
John Tucker (CEO)
Thank you, PJ, and thanks to everyone listening to this afternoon's call and webcast to review our first quarter 2024 results. As has been our practice, I will begin with an operational update before turning the call over to Steve Parsons, our Senior Vice President of Commercial, for a more detailed commercial update on FUROSCIX, and then Rachael Nokes, our Chief Financial Officer, for review of our financials. We will then open the call for your questions. During the first quarter, we saw a continuation of the positive trend that we believe reflect growing awareness and utilization of FUROSCIX as a new and
innovative part of a heart failure care continuum. As Steve will detail shortly, our leading indicators, including doses written, unique prescribers, and in-services completed, suggest that providers are increasingly more comfortable prescribing FUROSCIX to their heart failure patients during critical intervention windows, which are pre-hospital admission or post-discharge. We reported net revenue of $6.1 million, despite experiencing approximately 10% negative impact on doses filled during the quarter due to the widely reported and previously disclosed Change Healthcare cyber attack.
We also experienced some seasonal impact during the first quarter as patient deductibles reset with the new year. We continue to take steps to increase and improve our prescription fill rate. In March, we transitioned our patient service provider, or as we call it, the hub, which we think will result in an improved patient and physician experience. We are very pleased that turned in another solid quarter, notwithstanding these temporary headwinds. Our gross-to-net discount during the first quarter was 19%, up slightly from 2023.
We continue to expect the GTN discount to increase over time as contracting with payers and the marketplace evolves. We expect that the GTN discount will approach 30%-35% on a quarterly basis by the end of this year, consistent with our prior long-term guidance for GTN. Inventory levels at the end of the first quarter at our specialty pharmacy partners were generally consistent with the inventory levels at the end of 2023. Shifting now to payers. We continue to have productive discussions with commercial, Medicare Part D and Medicaid payers in an ongoing effort to make FUROSCIX broadly available to
patients at the most favorable terms possible. With favorable market dynamics in Medicare, we have expanded the population of heart failure patients who have access to FUROSCIX, a fixed tier copay of $100 or less to 70%, moving us closer to our previously stated goal of 75% or more over time. We are progressing with many other health plans, and we hope to have updates in the months to come. At this point, I would like to provide an update on several long-term growth initiatives that we previewed last quarter that we view as critical to our long-term growth strategy.
As we discussed previously, last year we received positive feedback from the FDA regarding the potential expansion of the FUROSCIX indication to allow for use in New York Heart Association Class IV heart failure patients. Recall that FUROSCIX is currently indicated for the treatment of congestion due to fluid overload in adult patients with New York Heart Association Class II and Class III chronic heart failure. We estimate that as many as 10% of all heart failure patients are Class IV, and a meaningful percent of these, as many as 40%, may benefit from FUROSCIX.
Based upon the feedback that we received from the agency, we filed for the Class IV indication in early October of last year, and we have been assigned a PDUFA date for this August, although the possibility does still exist that the PDUFA date could occur sooner. If we are successful, we believe Class IV would represent a meaningful expansion of our market opportunity, as providers would be able to prescribe FUROSCIX to the most severe heart failure patients. Turning now to the 80 mg over 1 ml low-volume auto-injector that we are developing as an additional option to the on-body infusor.
Just a few weeks ago, we announced that we initiated a pivotal PK study, and we plan to report results later this year, that, if successful, will allow us to submit a supplemental new drug application to the FDA by the end of this year. As we have stated previously, we believe an auto-injector, if approved, would reduce manufacturing costs compared to the current on-body infusor and confer environmental advantages as well. In addition to giving treating providers and their patients more treatment flexibility. Finally, we previously discussed feedback that we received from the FDA pertaining to the potential
expansion of the FUROSCIX indication to include treatment of edema due to fluid overload in patients with chronic kidney disease, or CKD. We recall that in its feedback, the FDA confirmed that no additional clinical studies are needed to expand the indication to CKD, provided that we can demonstrate an adequate PK and pharmacodynamic bridge to the listed drug, which is furosemide injection, 10 mg/ml. CKD is a progressive disease characterized by worsening renal function over time, resulting in frequent episodes of fluid overload that are treated with loop diuretics.
It is estimated that 12-15 million Americans are aware that they have kidney disease, and 50% of patients with CKD do not have a diagnosis of heart failure. With fluid overload being one of the most common complications in CKD, which worsens with disease progression, we believe FUROSCIX could be beneficial to patients with CKD who have worsening symptoms due to fluid overload and are not responding to oral loop diuretics. To that end, earlier this month, we submitted a Supplemental New Drug Application with the FDA for the CKD indication.
At this point, I'll turn the call over to our Senior Vice President of Commercial, Steve Parsons, for a deeper dive into our launch metrics. Steve?
Steve Parsons (Senior VP of Commercial)
Thank you. As John indicated, we continue to be pleased with our progress since launch. From launch in February 2023 through March 31st, 2024, we've had 2,184 unique prescribers, up 29% from the 1,696 unique prescribers we had from launch through December 31st. We are encouraged by the prescriber growth in this quarter, as we believe it reflects our strategy of establishing a broader prescriber base. Importantly, more than half of these prescribers have written multiple prescriptions. During the first quarter, we had 17,736 doses written, and 8,074 doses have been filled.
As John indicated earlier, our doses filled during the first quarter were negatively impacted by the widely reported Change Healthcare cyberattack. We also faced normal calendar seasonality as patient deductibles reset at the start of the year. Despite those headwinds, we are pleased with the trajectory that we are currently on, and we continue to explore steps to increase our fill rate going forward. One of those steps is a change in our patient services hub that we completed in March. An increasing number of our providers are writing prescriptions for patients in anticipation of future need.
These prescriptions may not be filled in the month or quarter in which they are written and make up a significant portion of the spread between doses written and doses filled that we report on. Pre-approved prescriptions are reported in the doses written statistics, and we report on them as doses filled when they actually ship to patients, as the prescriber directs. It's a portion of doses that do get canceled by prescribers or patients for a variety of reasons. Some patients are very difficult to reach or have been hospitalized or are deceased.
Other reasons for cancellation are a high copay or because the patient resolved with standard of care before filling FUROSCIX. The Change Healthcare situation did lead to an increase in cancellations during the quarter, as some prescriptions could not be processed when needed. Cancellation was 19% in quarter one of 2024. Over time, we anticipate that the cancellation rates will normalize. Better position on prescription formularies, quicker coverage decisions by payers, and lower patient out-of-pocket costs will improve fill rates and stabilize the percent that get canceled.
During the first quarter, the average number of doses per prescription filled was 6.1, which remains higher than our long-term expectations and up slightly sequentially from 5.9 in the fourth quarter of 2023. Our sales force has conducted 2,938 in-services from launch through March 31, up from 2,331 in-services completed as of December 31 of last year. In-services provide important training to offices on the prescribing process of FUROSCIX, and this ensures office readiness. As we open more new accounts, the execution of in-services remains fundamental to FUROSCIX success, and we regard the
number of in-services conducted each quarter as an important leading indicator. Regarding our sales force, we've said previously that we stand ready to add additional territories as demand warrants.... We plan on adding additional territories in advance of potential Class IV and CKD long-term growth initiatives. From a marketing perspective, we are engaged in a broad, multi-channel marketing campaign to drive brand awareness, adoption, and commitment. This program encompasses many different activities, but some of the key ongoing activities include engagement and development of key opinion
leaders, conference presence, print and electronic collateral, and the development of both provider and patient websites, among other critical tasks. We continue to reach out to heart failure patients and their caregivers with patient education materials for FUROSCIX. Overall, we are pleased with our continued progress and the path that we are on. That concludes my update. I would like now to turn the call over to our CFO, Rachael Nokes, for a review of our financials. Rachael?
Rachael Nokes (CFO)
Thank you, Steve. As of March 31, 2024, we held $58.4 million in cash and cash equivalents, compared to $76 million in cash, cash equivalents, and investments as of December 31, 2023. Now I will cover a few income statement items. We reported a net loss of $14.1 million for the first quarter of 2024, compared to a net loss of $11.2 million for the first quarter of 2023. Product revenues were $6.1 million for the first quarter of 2024, compared to $2.1 million for the first quarter of 2023.
Cost of product revenues were $1.8 million for the first quarter of 2024, compared to $0.6 million for the first quarter of 2023. The increase in both product revenues and cost of product revenues for the quarter ended March 31, 2024, was due to a full quarter of sales in the first quarter of 2024, and an increase in demand at FUROSCIX further into the commercial launch and related manufacturing costs. Research and development expenses were $2.7 million for the first quarter of 2024, compared to $2.1 million for the comparable period in 2023.
The increase in research and development expenses for the quarter ended March 31, 2024, was primarily due to an increase in device development costs, employee-related costs, and clinical study costs. Selling, general, and administrative expenses were $17.4 million for the first quarter of 2024, compared to $10.9 million for the comparable period in 2023. The increase in selling, general, and administrative expenses for the quarter ended March 31, 2024, was primarily due to an increase in employee-related costs, commercial costs, and patient support. As of March 31, 2024, we had
36,054,409 total shares outstanding. That concludes the financial update. John?
John Tucker (CEO)
Thanks, Rachael. This concludes our prepared remarks. At this point, we will open the call for questions.
Operator (participant)
Thank you. Ladies and gentlemen, if you would like to ask a question, please press star followed by one on your touchtone phone. You will then hear a prompt that your hand has been raised, and if you would like to withdraw from the question queue, simply press star followed by two. Out of consideration to other callers today, we ask that you please limit yourself to one question and one follow-up. Please go ahead and press star one now if you do have any questions. Your first question will be from Glen Santangelo at Jefferies. Please go ahead.
Glen Santangelo (Managing Director)
Yeah, thanks for taking my question. Hey, John or Rachael, I'm not sure who wants to answer, but I guess my first question is on revenues. Just sort of looking at the $6.1 million is sort of flat sequentially from where you were in 4Q, and I'm just trying to reconcile that versus the fact that the doses filled was up 15% sequentially. So I just wanna make sure I understand how the math and all that revenue recognition works.
John Tucker (CEO)
Yeah, sure, Glen. This is John. So in the Q1 was similar to the last quarter. Again, we had the impact of the Change Healthcare, which knocked that down. You know, you always have the headwinds in Q1 of patients out-of-pockets resetting. But the difference in the higher amount of doses billed versus last quarter and why the revenue stayed the same, was just in Q4 we had, as we talked about on the Q4 call, a very large order from Kaiser Direct that doesn't go into our billed doses, but is in our net revenue. So that's why there's a difference between what you would think the difference in the net revenue would be from doses filled.
Glen Santangelo (Managing Director)
All right, I'll go back and take a look at that. And then, John, maybe just one quick follow-up. Obviously, a lot of people are focused on the, the compelling value proposition for the managed care companies, but, you know, maybe either you or Steve can just sort of give us some sense of, of how the conversations are going with, with the, the feedback from the doctors. And, and are you getting any pushback at all at this point in terms of, you know, wanting to prescribe more, what the barriers are, are to, to prescribing more? Thank you.
John Tucker (CEO)
Sure, Steve, you wanna handle that?
Steve Parsons (Senior VP of Commercial)
Yeah. We're not getting pushback from the doctors. You can see our demand is going up and up, month-over-month. Continuing our conversations with payers. You know, most of our prescriptions are getting covered, and they're getting covered at affordable copays. As you heard John say, 70% of our copays are $100 or less. You know, we're engaging with them. They're all calculating what they're gonna do in 2025. So, you know, we're meeting with them regularly, and it's been pretty positive for us. So, and the docs aren't having an issue really at all getting the product that they want.
Glen Santangelo (Managing Director)
Okay, thank you.
John Tucker (CEO)
Thanks, bye.
Operator (participant)
Next question will be from Stacy Ku at TD Cowen. Please go ahead.
Stacy Ku (Biotech Equity Research Analyst)
Hey, thanks so much for taking our questions. Congratulations on the progress, especially navigating the Change Healthcare cyberattack. So, we just had a few questions. First, sounds like we're seeing good prescriber and patient demand. So can you just comment on expectations regarding seasonality this year? And if so, if you think there is gonna be seasonality, what do you have planned that could allow you to capture patient share during crucial high-demand quarters? You're just trying to get a lot of infrastructure in place ahead of the summer, for instance- where you might have a, a higher need for
FUROSCIX, unfortunately. And then the second question is gonna be around formulary additions. So when you talk about the hospital systems, and it, and it comes to kind of the FUROSCIX opportunity, how are you thinking about it long term, and, and how long do you expect that process will take with kind of IDNs and, and, and kind of formulary access? So where are you in that progress as we think about account targets? Thank you so much.
John Tucker (CEO)
Thanks, Stacy. It's John. I'll speak comment as well. Seasonality, you know, it's interesting, so there's several seasonality. You know, you get an impact in Q1, mainly because out-of-pockets reset, patients' deductibles and their out-of-pockets reset. So there's always a little headwind in Q1. If you look at Q2, Q3, we don't see that same seasonality. Into the end of Q4, you know, second half of Q4, you have something Steve calls holiday heart, where patients are, you know, doctors are worried they're gonna grab too much salt.
So you tend to see doctors writing a lot more scripts, kind of, for the patients, just in case, and a lot of the patients end up using them. So I do think there's some seasonality based on the holidays in Q4. We don't see it quite as much like around July 4th or something, as opposed to Christmas and Thanksgiving. So the question on the IDNs, I guess jump in. So, you know, IDNs come in all shapes and sizes. Obviously, the biggest one is the VA. Our goal this year is to get on national formulary. The VA, we're selling to VAs, you know, every month to separate VAs, but again, we want to go up a national formulary.
The second biggest VA is Kaiser. We've talked about the formulary there and did ship a big, almost 1,000-unit order there at the end of Q4. And they put it in their protocols, so they're using it now on patients. So we anticipate them continuing to order. That's your second-biggest IDN. And then you have a number of IDNs, again, IDNs all look different, that are sometimes this hospital system. Maybe, Steve, you can talk about some of the ones we're working with now.
Steve Parsons (Senior VP of Commercial)
Yeah. For example, the University of California system, that's UC Davis, UC San Francisco, UCLA, San Diego, Irvine. We're working with them to for them to direct purchase FUROSCIX, put it into all of their sites, load it into their EMR so they're fully integrated. It's really fast, real easy, you know, having that integration, you know, having the patient information and being able to see who got what, when, across the whole system. So that's one that's, you know, Q2, we think. There's other ones all over the country like that. Think of, think of big IDNs or that are academic or, you know, university systems.
They, they have the same interest in, in bringing FUROSCIX in directly and giving their patients access through, through them.
Stacy Ku (Biotech Equity Research Analyst)
Okay. Okay, very helpful. Thank you so much.
Operator (participant)
Thank you. Next question will be from Roanna Ruiz at Leerink Partners. Please go ahead.
Roanna Ruiz (Senior Managing Director)
Great. Afternoon, everyone.
John Tucker (CEO)
Good afternoon.
Roanna Ruiz (Senior Managing Director)
I noticed you mentioned you completed a transition to a new patient services provider and specialty pharmacy network. I was curious, does that impact inventory or stocking at all? And could it help streamline or even boost the process of getting FUROSCIX to patients?
John Tucker (CEO)
So it doesn't really impact our inventory at all, but yes, we're really looking to improve the patient and physician experience, streamline getting product to patient as fast as we can, and actually get better data as well. So that was the reason we made the change, but it didn't have any impact on inventory.
Roanna Ruiz (Senior Managing Director)
Got it. Okay. And as a follow-up, I was curious, knowing that the PDUFA date is coming up in August for Class IV heart failure, do you plan to do anything different with the field force strategy, educating physicians at that time, et cetera, to help boost FUROSCIX education and awareness, ahead of the label expansion?
John Tucker (CEO)
Yeah, as soon as, you know, you can't pre-promote that, but as soon as we have the approval, we'll be doing mailings and notification to all, you know, providers. And obviously, the sales force would have been trained in advance of that. Keep in mind, it's the same—it's really the same physicians that we're calling on, so we'll be educating them through direct and non-direct routes that, hey, this is, these patients are now eligible for FUROSCIX use. So it'll be, again, direct and non-direct promotion awareness to the physicians that we now have Class IV indication, but it's the same docs, the same in the same offices.
Roanna Ruiz (Senior Managing Director)
Got it. Thanks.
Operator (participant)
Thank you. Next question will be from Chase Knickerbocker at Craig-Hallum Capital. Please go ahead.
Chase Knickerbocker (Senior Equity Research Analyst)
Good afternoon. Thanks for taking my questions as well. Maybe just to start, might have missed this, but just to confirm, you've seen kinda that script fill rate normalize thus far in April, where it's kinda back to your usual expectations. And along those same lines, any reason to believe that, you know, doses written could have potentially been, you know, partially impacted, as well as physicians maybe were a little less confident around potential script approval in March when we were in the heat of the change situation? Thanks.
John Tucker (CEO)
You know, Chase, we don't think so. We were looking at the prescription trends coming in as we were going through the cyberattack. There might have been a little lull, but it wasn't anywhere near what we were seeing on the fill side. And, you know, doctors knew what was going on. Don't forget, the doctors weren't getting paid 'cause their claims weren't getting paid at all. So, there might have been a little slowdown, nothing we could really see that it. I was worried it would cut some momentum out from underneath us, but we don't think so, 'cause we saw scripts really growing through the end of the
quarter into this quarter, especially. So, any impact, we really think it was contained in Q1 and really was the impact on doses shipped.
Chase Knickerbocker (Senior Equity Research Analyst)
Got it. And that doses shipped has certainly normalized to normal expectations so far in Q2, just to -- yeah.
John Tucker (CEO)
Yep, correct. Back to, get back to, back to the similar level where we were before Change.
Chase Knickerbocker (Senior Equity Research Analyst)
Great. Is it time for us to kind of adjust our thinking on average doses per script? Then how does that also kind of, that same question, does that become a little bit more relevant as well when we contract with some of the larger Medicare Advantage plans? Are they gonna kind of force a cap of 4 doses per script on the Medicare Advantage side when that's contracted? Maybe just kind of help us with our long-term expectations around doses per script.
John Tucker (CEO)
So it, it's still higher than we anticipated. I do think Change might have had a little impact on it because if they were gonna get a script through, they were gonna make sure, you know, it, it was a six or a seven. We do think with plans, that plans will, will bring that back down. You know, our contract with United on their commercial formulary is a, is a script of four. We think as more and more plans adopt it, that that will help moderate it. But it's important to note, we're still seeing about 75% of our business be the, you know, the pre-acute, the pre-admission patient, and we just know those doses are gonna be, are gonna be 5s and
6s. So I think that combination of things. But I, but I, but I do think it will come back down. Is it gonna come all the way back down to four? We don't, we don't think so anymore. I think we're thinking it moderates in the five area.
Chase Knickerbocker (Senior Equity Research Analyst)
Got it. And you kinda mentioned on Kaiser's, you know, protocols around how they're using FUROSCIX. Can you kinda give us a look into there on how an IDN like Kaiser, you know, could be utilizing your product? Is it largely on the front end, pre-acute? Is it post-acute after, you know, just to prevent readmissions? Like, where are they really leaning into FUROSCIX? And kinda talk about their experience thus far that you've heard.
Steve Parsons (Senior VP of Commercial)
So this is Steve. Their experience, what they're doing is a little different than what we've seen in the preventing admission. Their hospitalists, their home care staff, they're prescribing for post-discharge pretty regularly to prevent that readmission. That's their first use case of it. We know that will expand to, you know, pre-admission to save on an unnecessary hospitalization. But they are a little different than what we see. They're their own animal, and they, you know, always think a little differently than everybody else. So, that is a nuanced difference, but we expect it to be used in both cases over the long haul.
Chase Knickerbocker (Senior Equity Research Analyst)
Got it. Thanks for taking the questions, guys.
John Tucker (CEO)
Thanks, Chase.
Operator (participant)
Ladies and gentlemen, a reminder to please press star one if you have any questions. Next will be Naz Rahman at Maxim Group. Please go ahead.
Naz Rahman (VP of Biotech Equity Research)
Hi, everyone. Congrats on the progress. Just, a couple. On the upcoming Class IV and also CKD potential launches, could you comment on what you think the number of doses might be for those indications?
John Tucker (CEO)
Mm-hmm. Steve, you wanna-
Steve Parsons (Senior VP of Commercial)
I would say for Class four, they are a little bit sicker. They are more severe. They tend to have excess fluid more often and more times a year, where they lose control a little bit. So I don't think the script size will moderate down for the Class IV patients specifically. It could be in that 6 range or, maybe they'll get refills more often than, you know, a standard patient. For CKD, our market research tells us it's about the same as heart failure. You know, it'll be in that 4-5 range, unless they're sicker with chronic kidney disease and have more fluid, and then it might be similar to a Class IV in heart failure.
Naz Rahman (VP of Biotech Equity Research)
Got it. Thanks. That was helpful. And, my last question is on, you mentioned that an increasing number of providers are writing scripts in anticipation of future needs. Do you have an idea of what percentage of the scripts providers are writing that are for potential future needs?
John Tucker (CEO)
So it's sometimes hard to tell. You can look at the expedited ones because those are definitely needed, but I think it's 20% or so that they kind of put on layaway.
Naz Rahman (VP of Biotech Equity Research)
Got it. Thanks. Thank you for taking my question.
John Tucker (CEO)
Thanks.
Operator (participant)
Next is Douglas Tsao at H.C. Wainwright. Please go ahead.
Douglas Tsao (Managing Director)
Hi, good afternoon. Thanks for taking the questions. Just, John, maybe as a follow-up, I guess, in terms of the physicians who are prescribing in advance, can you maybe just help us understand how far in advance that is? And maybe what's the sort of process between them or sort of the value of writing the script? I mean, I guess, is it just pre-adjudicated, and then it sort of ships when they tell you to ship it?
John Tucker (CEO)
Yeah. Hey, Doug, it's John. Yes, you know, we filled one from January, September, I saw last week, that was put on layaway. The doctor checked to make sure, you know, that everything cleared, and understood what the, what the copay was, and then as soon as the patient ran into trouble, the doc was ready to send it to the patient. So, Steve, do you want to-
Steve Parsons (Senior VP of Commercial)
Yeah, I think that's certainly an example that these prescriptions aren't gone. They're not lost. They're not canceled. Every week, we see prescriptions coming, you know, getting filled from, you know, months ago. But the most common utilization is the doctor sees a patient, they have some excess fluid, they have symptoms, it's maybe it's early. They order FUROSCIX because they think they might need it. The patient progresses, they do the normal standard of care a little bit. If that doesn't work, they immediately call down FUROSCIX. So sometimes these layaway scripts are only a matter of days.
Other times, you know what? I know we have a group of frequent flyers. Let's just send in a few prescriptions, get those approved. Let's get the known copay. Let's get it all ready to go, and when we see them, if they're in trouble, we'll just call it down. So it's good housekeeping for them in some cases, in terms of fluid management. Other cases, they just want to see if the patient resolves under standard of care, and then in some cases, it is filled, you know, more remotely from when it was prescribed.
Douglas Tsao (Managing Director)
Okay, great.
Steve Parsons (Senior VP of Commercial)
All over, I should say. Highly variable.
Douglas Tsao (Managing Director)
And then a follow-up. I mean, it sounds like you sort of navigated the Change Healthcare disruption well. I'm just curious if you have a sense of, you know, how many scripts you ultimately lost, or was it just a matter that most of them ultimately just fell out of the first quarter and maybe were filled in 2Q?
John Tucker (CEO)
No, I think I don't think they were filled in Q2, Doug. I think we, you know, we said about 10% of units, if you look at units, that if you, if you looked at what we were filling and, it was about ten-- we think it's about 10%. When we looked at what was coming in, that should have been going out, that wasn't going out. It was higher than that. We recovered, and some of them did ship later in March, so we recovered some of them. I was worried it was going to be closer to 20 or 25% because it was just shut down, but I think we recovered most of it. So we think we lost about $600,000 or $700,000 in there.
Douglas Tsao (Managing Director)
Okay, great. Thank you so much.
Operator (participant)
Thank you. At this time, I would like to turn the call back over to Mr. John Tucker.
John Tucker (CEO)
Thank you. Okay, that concludes our call this afternoon. We are very pleased with our first quarter results, which we generated notwithstanding the headwinds of the Change Healthcare cyberattack and an annual resetting of out-of-pocket patient deductibles. We expect this momentum to continue as more treating physicians gain comfort prescribing FUROSCIX to their heart failure patients and as we make incremental progress with payer formulary. At the same time, we are excited about our lifecycle initiatives, having had productive discussions with the FDA, and look forward to providing more updates
as we progress through 2024. Look forward to a successful year, providing our next quarterly update in August. Thank you again, and have a good evening.
Operator (participant)
Thank you, sir. Ladies and gentlemen, this does indeed conclude the conference call for today. Once again, thank you for attending, and at this time, we do ask that you please disconnect your lines.